Impact of MammaPrint on Clinical Decision-Making in South African Patients with Early-Stage Breast Cancer-Reference-Cited by-同舟云学术

Impact of MammaPrint on Clinical Decision-Making in South African Patients with Early-Stage Breast Cancer

Published:2016-04-14 Issue:4 Volume:22 Page:442-446
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast J

Author:

Pohl Heinrich¹,Kotze Maritha J.²,Grant Kathleen A.²³,van der Merwe Lize⁴⁵,Pienaar Fredrieka M.⁶,Apffelstaedt Justus P.¹,Myburgh Ettienne J.¹⁷^ORCID

Affiliation:

1. Department of Surgery; University of Stellenbosch; Tygerberg South Africa

2. Division of Anatomical Pathology; Department of Pathology; Faculty of Medicine and Health Sciences; University of Stellenbosch; Tygerberg South Africa

3. Department of Biomedical Sciences; Faculty of Health and Wellness; Cape Peninsula University of Technology; Bellville South Africa

4. Division of Molecular Biology and Human Genetics; Faculty of Medicine and Health Sciences; University of Stellenbosch; Tygerberg South Africa

5. Department of Statistics; University of the Western Cape; Bellville South Africa

6. GVI Oncology; Mediclinic Panorama; Cape Town South Africa

7. Private Practice; Mediclinic Panorama; Cape Town South Africa

Funder

South African Department of Science and Technology

Cancer Association of South Africa

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tbj.12605/fullpdf

Reference10 articles.

1. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer;Ravdin;J Clin Oncol,2001

2. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations;Iwamoto;Breast Cancer Res Treat,2011

3. Is Oncotype DX recurrence score (RS) of prognostic value once HER2-positive and low-ER expression patients are removed?;Milburn;Breast J,2013

4. Incorporating microarray assessment of HER2 status in clinical practice supports individualised therapy in early-stage breast cancer;Grant;Breast,2015

5. MammaPrint Prescreen Algorithm (MPA) reduces chemotherapy in patients with early stage breast cancer;Grant;S Afr Med J,2013

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the genomic signature of 70-genes for breast cancer in the public system and in supplementary health care in a country of medium socioeconomic development;The Breast;2024-08

2. Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach;Human Pathology Reports;2021-11

3. The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa;The Breast;2021-10

4. A risk prediction model of gene signatures in ovarian cancer through bagging of GA-XGBoost models;Journal of Advanced Research;2021-05

5. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis;Health Technology Assessment;2019-06